Yield10 Bioscience

Yield10 Bioscience Net Debt / EBITDA

The Net Debt to EBITDA of Yield10 Bioscience (YTENQ) as of Nov 3, 2026 is 1.29. In the previous year, Net Debt to EBITDA was 0.62 — a change of 107.64% (higher).

Net Debt / EBITDA

1.29

YoY

107.64%

Last updated:

Net Debt to EBITDA of Yield10 Bioscience is 2019 1.29 . Net Debt to EBITDA of Yield10 Bioscience was 2018 0.62 . It decreases by 107.64% higher compared to the previous year.

The Yield10 Bioscience Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2012
-3.72 USD
Jan 1, 2013
0.27 USD
Jan 1, 2014
0.75 USD
Jan 1, 2015
0.99 USD
Jan 1, 2016
0.71 USD
Jan 1, 2017
1.56 USD
Jan 1, 2018
0.62 USD
Jan 1, 2019
1.29 USD
The Yield10 Bioscience Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.29+107.64%
0.62-60.17%
1.56+119.39%
0.71-27.80%
0.99+32.32%
0.75+176.29%
0.27-107.26%
-3.72-777.77%
0.55+70.75%
0.32+15.12%
0.28-58.61%
0.67+0.37%
0.67-53.34%
1.44+493.96%
0.24-55.15%
0.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Yield10 Bioscience Stock analysis

What does Yield10 Bioscience do? Yield10 Bioscience develops Camelina sativa as a platform crop for low carbon sustainable seed products, including Camelina oil for biofuel feedstock, Omega-3 oils for nutrition, and PHA Bioplastics for biodegradable packaging. The company uses its TraitFactory platform to discover genetic traits for agriculture and food industries, focusing on herbicide tolerance and disease resistance in Camelina germplasm. Its products target petroleum replacement markets, food and nutrition sectors, and animal feed markets, with development pipelines focused on improving Camelina varieties. The company's primary products are Camelina oil, Omega-3 oils, and PHA Bioplastics, sold to markets addressing petroleum replacement, nutrition, and sustainable packaging needs. Camelina sativa serves as the core crop for all seed product development, with TraitFactory enabling trait discovery for agricultural and food applications. The firm targets industrial buyers in biofuel, nutrition, and packaging industries seeking sustainable alternatives to petroleum-based products. Yield10 Bioscience's revenue streams come from the sale of Camelina-based products to companies in the biofuel, nutrition, and packaging sectors. The company focuses on developing high-value genetic traits through TraitFactory, which are integrated into Camelina varieties for large-scale production of seed products. Its development pipeline emphasizes traits like herbicide tolerance and disease resistance to enhance crop performance and market appeal. Yield10 Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yield10 Bioscience stock

Net Debt to EBITDA of Yield10 Bioscience is 1.29 in 2019.

Net Debt to EBITDA of Yield10 Bioscience changed from 0.62 to 1.29, representing a 107.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Yield10 Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Yield10 Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Yield10 Bioscience

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Yield10 Bioscience